C. R. Bard, Inc.

C. R. Bard, Inc. is a US-based company focused on medical technology, delivering innovative products designed to advance healthcare through enhanced patient care and safety in medical procedures.

C. R. Bard, Inc. specializes in developing and manufacturing medical devices.

The company is headquartered in Murray Hill, New Jersey, and operates globally with offices across North America, Europe, and Asia Pacific. Founded in 1907 by Charles R. Bard, the company has undergone various expansions and technological advancements over the years, continually evolving its product lines to meet healthcare demands. The current CEO is Frank Maloit, who leads the company in its strategic initiatives.

C. R. Bard, Inc. develops a comprehensive array of medical technologies including catheters, surgical instruments, and implantable devices.

Their flagship offerings encompass urethral, vascular, and oncological products, as well as systems that enhance patient safety and streamline healthcare delivery. Bard's products are widely utilized in hospitals and outpatient settings globally, ensuring effective management of patient care. C. R.

Bard, Inc. generates revenue through direct sales of medical devices to healthcare providers, including hospitals and outpatient facilities. The revenue model consists of both B2B sales as well as consumer sales. Noteworthy products significantly contribute to revenue through one-time and recurring orders, as healthcare facilities consistently require Bard's medical technologies to ensure patient safety and operational efficiency.

C. R. Bard, Inc. plans to introduce several new products aimed at addressing the evolving needs of healthcare professionals and patients.

Specifically, the company is working on launching new vascular access solutions by the end of 2024. Furthermore, Bard aims to expand its reach into emerging markets in Asia and Latin America by 2025, leveraging its established relationships and product innovations to capture new opportunities. Recent funding will be allocated to enhance R&D capabilities and support marketing efforts in these targeted regions.